Combination therapy of doxorubicin and CD47 mAb has shown success in different cancers (Feliz‐Mosquea et al., 2018; Iribarren et al., 2019; Li et al., 2018; Wu et al., 2018) but their efficacy in osteosarcoma remains unknown. This evidence concerns the gene CD47 and osteosarcoma.